Search research articles
Contact Us
Filters
Showing results (21-30 of 127) with videos related to
Page
of 13
Sort By:
Archives of Neurology
|
March 1, 1992
Cytokine secretion by multiple sclerosis monocytes. Relationship to disease activity
R A Rudick, R M Ransohoff
CNS Drugs
|
January 23, 2013
Prescribing recommendations for interferon-Beta in multiple sclerosis
B Weinstock-Guttman, R A Rudick
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
October 3, 2002
The multiple sclerosis functional composite: a new clinical outcome measure for multiple sderosis trials
R A Rudick, G Cutter, S Reingold
Archives of Neurology
|
October 1, 1987
The GABA-agonist progabide for spasticity in multiple sclerosis
R A Rudick, D Breton, R L Krall
Archives of Neurology
|
October 1, 1989
Exacerbation rates and adherence to disease type in a prospectively followed-up population with multiple sclerosis. Implications for clinical trials
D E Goodkin, D Hertsgaard, R A Rudick
Neurology
|
August 1, 1987
Free light chains in multiple sclerosis and infections of the CNS
C DeCarli, M A Menegus, R A Rudick
Cleveland Clinic Journal of Medicine
|
January 1, 1992
Experimental therapies for multiple sclerosis: current status
D E Goodkin, R M Ransohoff, R A Rudick
Cleveland Clinic Journal of Medicine
|
May 1, 1992
Pharmacotherapy of multiple sclerosis: current status
R A Rudick, D E Goodkin, R M Ransohoff
Archives of Neurology
|
May 1, 1994
The use of brain magnetic resonance imaging in multiple sclerosis
D E Goodkin, R A Rudick, J S Ross
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
May 1, 2007
Optimal reference population for the multiple sclerosis functional composite
R J Fox, J-C Lee, R A Rudick
Page
of 13
Search research articles
Search
Showing results (21-30 of 127) with videos related to
Sort By:
Page
of 13
Archives of Neurology
|
March 1, 1992
Cytokine secretion by multiple sclerosis monocytes. Relationship to disease activity
R A Rudick, R M Ransohoff
CNS Drugs
|
January 23, 2013
Prescribing recommendations for interferon-Beta in multiple sclerosis
B Weinstock-Guttman, R A Rudick
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
October 3, 2002
The multiple sclerosis functional composite: a new clinical outcome measure for multiple sderosis trials
R A Rudick, G Cutter, S Reingold
Archives of Neurology
|
October 1, 1987
The GABA-agonist progabide for spasticity in multiple sclerosis
R A Rudick, D Breton, R L Krall
Archives of Neurology
|
October 1, 1989
Exacerbation rates and adherence to disease type in a prospectively followed-up population with multiple sclerosis. Implications for clinical trials
D E Goodkin, D Hertsgaard, R A Rudick
Neurology
|
August 1, 1987
Free light chains in multiple sclerosis and infections of the CNS
C DeCarli, M A Menegus, R A Rudick
Cleveland Clinic Journal of Medicine
|
January 1, 1992
Experimental therapies for multiple sclerosis: current status
D E Goodkin, R M Ransohoff, R A Rudick
Cleveland Clinic Journal of Medicine
|
May 1, 1992
Pharmacotherapy of multiple sclerosis: current status
R A Rudick, D E Goodkin, R M Ransohoff
Archives of Neurology
|
May 1, 1994
The use of brain magnetic resonance imaging in multiple sclerosis
D E Goodkin, R A Rudick, J S Ross
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
May 1, 2007
Optimal reference population for the multiple sclerosis functional composite
R J Fox, J-C Lee, R A Rudick
Page
of 13